80.05
+0.44%
Close of 9 Nov 2026, in CHF
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BACHEM HOLDING
Its shares trade on SIX under the ticker BANB.SW. It has been listed since 29 June 2001. In the fiscal year to 31 December 2025, it reported revenue of CHF 695.1m and net income of CHF 148.8m. At that date it held total assets of CHF 2.11bn and shareholders' equity of CHF 1.46bn.
Bachem Holding AG is a technology-based biochemical company, which engages in the provision of services to the pharmaceutical and biotechnology industries. The company is headquartered in Bubendorf, Basel-Landschaft. The company went IPO on 2001-06-29. The firm focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The firm markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 29 Jun 2001
- Employees
- 1,475
- Website
- bachem.com ↗
Leadership
Pay as last reported
- Dr. Kuno SommerNon-Executive Chairman of the BoardCHF 210,000
- Mr. Thomas MeierChief Executive Officer, Chief Operating Officer, Member of the Corporate Executive CommitteeCHF 762,000
- Ms. Nicole HoetzerNon-Executive Vice Chairwoman of the BoardCHF 106,000
- Mr. Alain SchaffterChief Financial Officer, Member of the Corporate Executive Committee
- Mr. Guenther LoidlChief Technology Officer, Member of the Corporate Executive Committee
- Mr. Torsten WohrChief Commercial Officer, Member of the Corporate Executive Committee
- Dr. Alex FaesslerNon-Executive Director, since 2017CHF 107,000
- Dr. Steffen LangNon-Executive DirectorCHF 106,000
- Prof. Dr. Helma WennemersNon-Executive DirectorCHF 103,000
- Dr. Daniel GrotzkyHead - Group Communications, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 46
- Environment
- 2
- Social
- 89
- Governance
- 47
- Direct emissions (scope 1)
- 5,888 t
- Energy emissions (scope 2)
- 2,123 t
- Value chain emissions (scope 3)
- 119,660 t
- Women in the workforce
- 30.4%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bachem Holding AG employs 1,475 full-time employees in Switzerland and the United States.
- Bachem and Clinalfa are well-known brands in the Life Sciences Tools & Services sector.
- Bachem provides fluorescent dyes for FRET analysis of receptor-ligand interactions.
Weaknesses
- Bachem's production facilities are limited to Switzerland and the United States only.
- Bachem's focus on peptides and organic molecules may restrict market diversification.
- Bachem's IPO date was 29 June 2001, which is over two decades old.
Opportunities
- Bachem can expand its product portfolio with glycosylated peptides for drug property manipulation.
- Bachem can leverage its expertise in biochemical products for research purposes.
- Bachem can target new markets in the Health Care sector.
Threats
- Bachem faces competition from other Life Sciences Tools & Services providers in Switzerland and the United States.
- Bachem's reliance on the pharmaceutical industry may lead to market volatility.
- Bachem's business model depends on the continued demand for active pharmaceutical ingredients (APIs).
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.